Dear Colleagues,

 

PDA and the European Medicine Agency welcome you to the 2011 PDA-EMA Conference in London. Planning for this year’s conference, the fourth in this series, started in May of 2010 with the recruitment of our superb scientific planning committee. The committee has worked over the intervening months to bring you a very special program. The 2011 Conference will be a milestone as there has been a decision to broaden the agenda beyond Good Manufacturing Practice (GMP) to include a full range of quality issues relating to pharmaceutical development, production and quality management. The committee’s input from EMA’s Quality Working Party (QWP), Biologics Working Party (BWP) and GMP/GDP Inspectors Working Group has resulted in substantial CMC-related content in the agenda. The agenda has been extended from 1¾ days to a full 2½ days, and the number of concurrent tracks increased from 3 to 5, to make room for the expanded content. The number of EMA speakers, and speakers from the national health authorities, is impressive due in part to the convenience of the conference venue near London’s Heathrow Airport.

 

As a result of these efforts we present to you the 2011 PDA-EMEA Conference, with the theme, “Regulation | Cooperation | Innovation: An Effective Partnership between Authorities and Industry in Europe.” The plenary sessions on each morning of the conference will address universal themes of interest to all segments of our business. The five parallel tracks on the afternoons of 3 & 4 May will provide ½ day of coverage to more detailed technical or regulatory topics. The parallel tracks include: Process optimisation, Quality, Regulatory Affairs, Advanced Therapies, Supply Chain, Trends in Manufacturing, Biologics and Orphan Drugs (some tracks are repeated two times). There will be interactive panel discussions capping each of the parallel tracks. The planning committee has also focused on issues of interest to ‘Start-up’ and small & medium enterprises (SME). We have listened to your comments and evaluations from the 2006, 2008 & 2009 conferences, and have structured the agenda in a way to allow ample time for questions, answers and discussion. Full preliminary information can be found below in this preliminary brochure. Please join us in London for this very special and unique opportunity to learn more about the future of pharmaceutical quality, GMP, development and manufacturing in our business.

 

 

 

 

 

David Cockburn, EMA
Nick Gate, EMA
Steffen Gross, Paul-Ehrlich-Institut, Germany
Anne Junttonen, FIMEA, Finland
Vassiliki Revithi, EOF, Greece
Peter Richardson, EMA
Jean-Louis Robert, Laboratoire National de Sante, Luxembourg & Head of QWP
Jean-Hugues Trouvin, AFSSAPS, France

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Source:PDA